KR20030061524A - Method for preparing arginine derivatives - Google Patents
Method for preparing arginine derivatives Download PDFInfo
- Publication number
- KR20030061524A KR20030061524A KR1020020002053A KR20020002053A KR20030061524A KR 20030061524 A KR20030061524 A KR 20030061524A KR 1020020002053 A KR1020020002053 A KR 1020020002053A KR 20020002053 A KR20020002053 A KR 20020002053A KR 20030061524 A KR20030061524 A KR 20030061524A
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- arginine derivative
- represented
- group
- arginine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
본 발명은 아르기닌 유도체의 제조방법에 관한 것으로, 더욱 상세하게는 아르기닌 유도체의 제조반응에 있어서, 보호기인 tert-부틸옥시카보닐기(카바메이트) 제거 단계에서 생성되는 염산염 형태의 반응중간체의 흡습에 의한 조해성을 해결하고, 동시에 삼차아민 염기의 사용량을 감소시킬 수 있는 아르기닌 유도체의 제조방법에 관한 것이다.The present invention relates to a method for preparing an arginine derivative, and more particularly, in the production reaction of an arginine derivative, by absorption of a hydrochloride-type reaction intermediate formed in the step of removing tert-butyloxycarbonyl group (carbamate), which is a protecting group. The present invention relates to a method for preparing an arginine derivative capable of resolving deliquescent properties and simultaneously reducing the amount of tertiary amine base used.
아르기닌 유도체는 일본공개특허공보 소 62-34035호에서 개시하듯이 항혈전증 치료제(inhibitor for thromboxane synthetase)의 원료로 사용가능한 이미 공지된 물질이다.Arginine derivatives are known materials that can be used as raw materials for inhibitors for thromboxane synthetase, as disclosed in Japanese Patent Laid-Open No. 62-34035.
이러한 아르기닌 유도체로서 tert-부틸옥시카보닐기(카바메이트)로 보호된 화합물들의 아민 위치에 다른 작용기를 도입시키기 위해 보호기를 제거하게 되는데, 대개의 경우에는 무수 조건의 염산을 사용하여 하기 화학식 5와 같은 중간체를 제조한다.As the arginine derivative, the protecting group is removed to introduce another functional group at the amine position of the compounds protected by the tert-butyloxycarbonyl group (carbamate). In most cases, anhydrous hydrochloric acid may be used to Prepare the intermediate.
[화학식 5][Formula 5]
(상기 화학식 5의 식에서,(In Formula 5,
R은 수소, 또는 탄소수 1∼5인 저급 알킬기이다)R is hydrogen or a lower alkyl group having 1 to 5 carbon atoms)
상기 화학식 2로 표시되는 중간체는 일본공개특허공보 소 62-34035호에 개시한 바와 같이, 하기의 반응식 1의 방법으로 제조된다.The intermediate represented by Chemical Formula 2 is prepared by the method of Scheme 1 below, as disclosed in Japanese Patent Laid-Open No. 62-34035.
[반응식 1]Scheme 1
상기의 방법에서는 보호기 제거 원료로 무수 염산을 사용하게 되는데, 이러한 방법에 의해 생성된 화합물은 아민에 대해 염산염 형태를 띠게 된다.In the above method, anhydrous hydrochloric acid is used as a raw material for protecting group removal, and the compound produced by this method has a hydrochloride form for the amine.
상기 화합물은 흡습성에 의한 조해성을 가진다. 상기 조해성으로 인하여 보호기 제거 단계 이후의 과정인 방향족 설포닐 화합물과의 결합 반응에 방해가 되며, 또한 생성물에 포함된 염산은 다음 반응에서 필히 제거해야 하기 때문에 반응에 필요한 삼차아민의 사용량이 최소 두 배 이상으로 필요하게 된다는 문제점이 있다.The compound has deliquescent property by hygroscopicity. The deliquescent properties interfere with the coupling reaction with the aromatic sulfonyl compound after the step of removing the protecting group, and since the hydrochloric acid contained in the product must be removed in the next reaction, the amount of the tertiary amine required for the reaction is at least doubled. There is a problem in that it is necessary.
상기와 같은 조해성을 방지하기 위한 방법으로는 에테르계의 유기 용매를 채운 상태에서 그대로 증류하는 방법과 습기가 제거된 특수한 환경에서 작업하는 방법이 있다. 그러나, 전자의 경우는 에테르의 폭발성이 우려되고, 후자의 경우에는 설비비용이 많이 드는 단점이 있다. 또한 염산을 이용한 반응은 0 ℃ 정도의 저온 상태에서 반응하기 때문에 반응 조건이 용이하지 않다는 문제점이 있다.As a method for preventing such degradability, there is a method of distilling as it is in a state filled with an ether organic solvent and a method of working in a special environment from which moisture is removed. However, in the former case, the explosiveness of the ether is concerned, and in the latter case, the installation cost is high. In addition, since the reaction using hydrochloric acid reacts at a low temperature of about 0 ° C., there is a problem that the reaction conditions are not easy.
따라서, 보호기인 tert-부틸옥시카보닐기(카바메이트) 제거 단계에서 생성되는 염산염 형태의 반응중간체의 흡습에 의한 조해성을 해결하고, 동시에 삼차아민 염기의 사용량을 감소시킬 수 있는 아르기닌 유도체의 제조방법에 대한 연구가 더욱 필요한 실정이다.Therefore, in the method for preparing an arginine derivative capable of solving the deliquescent property of the hydrochloride-type reaction intermediate formed in the step of removing the tert-butyloxycarbonyl group (carbamate), which is a protecting group, and at the same time reducing the amount of the tertiary amine base. More research is needed.
상기와 같은 문제점을 해결하고자, 본 발명은 보호기인 tert-부틸옥시카보닐기(카바메이트) 제거 단계에서 생성되는 염산염 형태의 반응중간체의 흡습에 의한 조해성을 해결하고, 동시에 삼차아민 염기의 사용량을 감소시킬 수 있는 아르기닌 유도체의 제조방법을 제공하는 것을 목적으로 한다.In order to solve the above problems, the present invention solves the deliquescent property by the absorption of the reaction intermediate in the form of hydrochloride in the tert- butyloxycarbonyl group (carbamate) removal step as a protecting group, and at the same time reduce the amount of tertiary amine base It is an object of the present invention to provide a method for preparing arginine derivatives.
본 발명의 다른 목적은 반응 조건이 용이한 아르기닌 유도체의 제조방법을 제공하는 것을 제공하는 것이다.It is another object of the present invention to provide a method for preparing an arginine derivative having easy reaction conditions.
상기 목적을 달성하기 위하여, 본 발명은 하기 화학식 1로 표시되는 아르기닌 유도체의 제조방법에 있어서,In order to achieve the above object, the present invention provides a method for producing an arginine derivative represented by the following formula (1),
하기 화학식 1로 표시되는 아르기닌 유도체의 제조방법에 있어서,In the manufacturing method of the arginine derivative represented by the following formula (1),
a) 하기 화학식 3으로 표시되는 아르기닌 유도체 화합물과 하기 화학식 4로a) an arginine derivative compound represented by the following Chemical Formula 3 and the following Chemical Formula 4
표시되는 할로카테콜보란을 반응시켜 tert-부톡시카보닐기(카바메이트)가By reacting the displayed halocatecholborane, tert-butoxycarbonyl group (carbamate)
제거된 하기 화학식 2로 표시되는 자유아민 상태의 아르기닌 유도체를 제To remove the arginine derivative of the free amine state represented by the formula (2)
조하는 단계; 및Coordinating; And
b) 염기로 삼차아민 존재하에서 상기 a)단계에서 제조한 자유아민 상태의 아b) a subunit of the free amine state prepared in step a) in the presence of a tertiary amine as base.
르기닌 유도체에 아릴설포닐할라이드 화합물을 반응시켜 아릴기가 결합된By reacting an arylsulfonyl halide compound with a leginine derivative,
하기 화학식 1로 표시되는 아르기닌 유도체를 제조하는 단계To prepare an arginine derivative represented by the formula
를 포함하는 아르기닌 유도체의 제조방법을 제공한다:It provides a method for preparing an arginine derivative comprising:
[화학식 1][Formula 1]
상기 화학식 1의 식에서,In the formula of Formula 1,
R1은 수소, 또는 탄소수 1∼5인 저급 알킬기이고,R 1 is hydrogen or a lower alkyl group having 1 to 5 carbon atoms,
Ar은 페닐, 나프탈레닐, 또는 퀴놀리닐인 방향족 작용기이다.Ar is an aromatic functional group which is phenyl, naphthalenyl, or quinolinyl.
[화학식 2][Formula 2]
상기 화학식 2의 식에서,In the formula (2),
R2는 수소, 또는 탄소수 1∼5인 저급 알킬기이다.R 2 is hydrogen or a lower alkyl group having 1 to 5 carbon atoms.
[화학식 3][Formula 3]
상기 화학식 3의 식에서,In the formula (3),
R3는 수소, 또는 탄소수 1∼5인 저급 알킬기이고,R 3 is hydrogen or a lower alkyl group having 1 to 5 carbon atoms,
BOC는 tert-부틸옥시카보닐기이다.BOC is a tert-butyloxycarbonyl group.
[화학식 4][Formula 4]
이하 본 발명을 상세하게 설명한다.Hereinafter, the present invention will be described in detail.
본 발명자들은 아르기닌 유도체의 제조 중 생성되는 염산염 형태의 반응중간체의 흡습에 의한 조해성을 해결하고, 삼차아민 염기의 사용량을 감소시킬 수 있는 방법에 대하여 연구하던 중, 아르기닌 유도체 화합물과 할로카테콜보란을 반응시켜 자유아민 상태의 아르기닌 유도체를 제조한 결과, 보호기인 tert-부틸옥시카보닐기(카바메이트) 제거 단계에서 생성되는 염산염 형태의 반응중간체의 흡습에 의한 조해성을 해결할 수 있고, 동시에 삼차아민 염기의 사용량을 감소시킬 수 있음을 확인하고, 이를 토대로 본 발명을 완성하게 되었다.The inventors of the present invention have studied argonine derivative compounds and halocatecholborane while studying a method for solving the deliquescent property of the hydrochloride-type reaction intermediate formed during the preparation of the arginine derivative and reducing the amount of the tertiary amine base. As a result of the preparation of the arginine derivative in the free amine state, it is possible to solve the deliquescent property due to the absorption of the reaction intermediate in the form of hydrochloride in the step of removing the tert-butyloxycarbonyl group (carbamate), which is a protecting group. It was confirmed that the amount can be reduced, and based on this, the present invention was completed.
본 발명은 상기 화학식 3으로 표시되는 아르기닌 유도체 화합물과 상기 화학식 3로 표시되는 할로카테콜보란을 반응시켜 상기 화학식 2로 표시되는 자유아민 상태의 아르기닌 유도체를 제조한 후, 염기로 삼차아민 존재 하에서 상기 화학식 1로 표시되는 아르기닌 유도체를 제조하는 것을 특징으로 한다.The present invention is prepared by reacting the arginine derivative compound represented by the formula (3) with a halocatecholborane represented by the formula (3) to prepare an arginine derivative of the free amine state represented by the formula (2), in the presence of a tertiary amine as a base It is characterized by preparing an arginine derivative represented by the formula (1).
본 발명의 제조방법은 하기 반응식 2, 및 반응식 3에 따른다.The preparation method of the present invention is according to the following Scheme 2, and Scheme 3.
[반응식 2]Scheme 2
상기 반응식 2의 식에서,In the formula of Scheme 2,
X는 염소, 브롬, 또는 요오드인 할로겐족 원소이다.X is a halogen group element which is chlorine, bromine or iodine.
본 발명에 사용되는 상기 화학식 4로 표시되는 할로카테콜보란은 상기 화학식 3으로 표시되는 아르기닌 유도체 화합물에 대하여 2 내지 3 몰당량으로 포함되는 것이 바람직하며, 더욱 바람직하게는 2.1 내지 2.6 몰당량으로 포함되는 것이다. 상기 할로카테콜보란은 B-클로로카테콜보란, B-브로모카테콜보란, 및 B-요오도카테콜보란으로 이루어지는 군으로부터 선택되어 사용할 수 있다.The halocatecholborane represented by Formula 4 used in the present invention is preferably included in 2 to 3 molar equivalents, more preferably 2.1 to 2.6 molar equivalents, relative to the arginine derivative compound represented by Formula 3 above. Will be. The halocatecholborane can be selected from the group consisting of B-chlorocatecholborane, B-bromocatecholborane, and B-iodocatecholborane.
상기 a)단계의 반응(반응식 2)에서는 반응용매로 염화메틸렌, 또는 클로로포름 사염화탄소 등의 할로겐화메틸 용매를 사용할 수 있다.In the reaction of Step a) (Scheme 2), a methyl halide solvent such as methylene chloride or chloroform carbon tetrachloride may be used as a reaction solvent.
[반응식 3]Scheme 3
상기 반응식 3의 식에서,In the formula of Scheme 3,
X는 염소, 브롬, 또는 요오드인 할로겐족 원소이고,X is a halogen group element that is chlorine, bromine or iodine,
R'은 수소, 또는 탄소수 1∼5인 저급 알킬기이다.R 'is hydrogen or a lower alkyl group having 1 to 5 carbon atoms.
본 발명에 사용되는 상기 삼차아민은 상기 화학식 1로 표시되는 아르기닌 유도체에 대하여 1 내지 2 몰당량으로 포함되는 것이 바람직하며, 더욱 바람직하게는 1.1 내지 1.5 몰당량으로 포함되는 것이다. 상기 삼차아민은 트리알킬아민, 피리딘 유도체, 및 이미다졸 유도체로 이루어지는 군으로부터 선택되어 사용할 수 있다.The tertiary amine used in the present invention is preferably included in 1 to 2 molar equivalents, more preferably 1.1 to 1.5 molar equivalents relative to the arginine derivative represented by the formula (1). The tertiary amine can be selected from the group consisting of trialkylamines, pyridine derivatives, and imidazole derivatives.
상기 b)단계의 반응(반응식 3)에서는 반응용매로 염화메틸렌, 또는 클로로포름 사염화탄소 등의 할로겐화메틸 용매를 사용할 수 있다. 또한 반응온도는 0 내지 50 ℃의 범위인 것이 바람직하고, 더욱 바람직하게는 10 내지 30 ℃의 범위인 것이다.In the reaction of step b) (Scheme 3), a methyl halide solvent such as methylene chloride or chloroform carbon tetrachloride may be used as the reaction solvent. Moreover, it is preferable that reaction temperature is the range of 0-50 degreeC, More preferably, it is the range of 10-30 degreeC.
이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예를 제시하나, 하기 실시예는 본 발명을 예시하는 것일 뿐 본 발명의 범위가 하기 실시예에 한정되는 것은 아니다.Hereinafter, preferred examples are provided to help understanding of the present invention, but the following examples are merely to illustrate the present invention, and the scope of the present invention is not limited to the following examples.
[실시예]EXAMPLE
실시예 1Example 1
(tert-부톡시카보닐기가 제거된 아르기닌 유도체 제조)(Preparation of arginine derivative from which tert-butoxycarbonyl group is removed)
아르기닌 유도체인 에틸 (2R, 4R)-1-[NG-니트로-N2-(tert-부톡시카보닐)-L-아르기닐)-4-메틸-2-피페리딘카르복시산 27.3 g을 용매인 염화메틸렌 130 mL에 녹였다. 이를 할로카테콜보란인 B-브로모카테콜보란 27.8 g을 용매인 염화메틸렌 500 mL에 녹인 용액에 상온에서 적가하였다. 이를 상온에서 1 시간 동안 교반한 후, 물 130 mL를 투입시키고 20 분 동안 교반한 후, 염화메틸렌 1,000 mL로 묽게 희석시켰다. 이 용액을 10% 수산화나트륨 수용액 200 mL으로 2회 세척하고 포화염화나트륨 용액 200 mL로 1회 세척하였다. 상기와 같이 분리된 유기층을 무수 황산마그네슘으로 건조하고, 용매를 감압증류하여 24.7 g의 에틸 (2R, 4R)-1-(NG-니트로-L-아르기닐)-4-메틸-2-피페리딘카르복시산 흰색 고체를 수득하였다.27.3 g of an arginine derivative ethyl (2R, 4R) -1- [N G -nitro-N 2- (tert-butoxycarbonyl) -L-arginyl) -4-methyl-2-piperidinecarboxylic acid is solvent It was dissolved in 130 mL of phosphorus methylene chloride. This was added dropwise at room temperature to a solution of 27.8 g of B-bromocatecholborane, halocatecholborane, dissolved in 500 mL of methylene chloride as a solvent. After stirring for 1 hour at room temperature, 130 mL of water was added and stirred for 20 minutes, and diluted with 1,000 mL of methylene chloride. This solution was washed twice with 200 mL of 10% aqueous sodium hydroxide solution and once with 200 mL of saturated sodium chloride solution. The organic layer separated as above was dried over anhydrous magnesium sulfate, and the solvent was distilled under reduced pressure to give 24.7 g of ethyl (2R, 4R) -1- (N G -nitro-L-arginyl) -4-methyl-2-pi. Ferridinecarboxylic acid white solid was obtained.
(아릴기가 결합된 아르기닌 유도체 제조)(Manufacture of arginine derivative in which aryl group is bonded)
상기 수득한 에틸 (2R, 4R)-1-(NG-니트로-L-아르기닐)-4-메틸-2-피페리딘카르복시산 24.7 g을 용매인 클로로포름 200 mL에 녹인 후, 5 ℃를 유지하였다. 여기에 삼차아민인 트리에틸아민 7.4 g과 아릴설포닐할라이드 화합물인 3-메틸-퀴놀린설포닐클로라이드 14.8 g을 순서대로 투입하였다. 이를 상온에서 3 시간 동안 교반한 후, 반응용액을 물 50 mL로 2회 세척하였다. 상기와 같이 분리된 유기층을 무수 황산마그네슘으로 건조하고 용매를 감압증류하여 관크로마토그래피법(클로로포름 : 메틸알코올 = 20 : 1)으로 정제하여 33.1 g의 비결정형 고체인 에틸 (2R,4R)-1-[NG-니트로-N2-(3-메틸-8-퀴놀린설포닐)-L-아르기닐)-4-메틸-2-피페리딘카르복시산 30 g을 수득하였다.24.7 g of the ethyl (2R, 4R) -1- (N G -nitro-L-arginyl) -4-methyl-2-piperidinecarboxylic acid obtained above was dissolved in 200 mL of chloroform as a solvent, and then maintained at 5 ° C. It was. 7.4 g of triethylamine which is a tertiary amine and 14.8 g of 3-methyl- quinolinesulfonyl chloride which are an arylsulfonyl halide compound were thrown in this order. After stirring for 3 hours at room temperature, the reaction solution was washed twice with 50 mL of water. The organic layer separated as described above was dried over anhydrous magnesium sulfate, the solvent was distilled under reduced pressure, and the residue was purified by column chromatography (chloroform: methyl alcohol = 20: 1) to obtain 33.1 g of an amorphous solid, ethyl (2R, 4R) -1. 30 g of-[N G -nitro-N 2- (3-methyl-8-quinolinesulfonyl) -L-arginyl) -4-methyl-2-piperidinecarboxylic acid were obtained.
실시예 2Example 2
(tert-부톡시카보닐기가 제거된 아르기닌 유도체 제조)(Preparation of arginine derivative from which tert-butoxycarbonyl group is removed)
아르기닌 유도체인 에틸 (2R, 4R)-1-[NG-니트로-N2-(tert-부톡시카보닐)-L-아르기닐)-4-메틸-2-피페리딘카르복시산 27.3 g을 용매인 염화메틸렌 130 mL에 녹였다. 이를 할로카테콜보란인 B-클로로카테콜보란 21.6 g을 용매인 염화메틸렌 500 mL에 녹인 용액에 상온에서 적가하였다. 이를 상온에서 1 시간 동안 교반한 후, 물 130 mL를 투입시키고 20 분 동안 교반한 후, 염화메틸렌 1,000 mL로 묽게 희석시켰다. 이 용액을 10% 수산화나트륨 수용액 200 mL으로 2회 세척하고 포화염화나트륨 용액 200 mL로 1회 세척하였다. 상기와 같이 분리된 유기층을 무수 황산마그네슘으로 건조하고, 용매를 감압증류하여 25.1 g의 에틸 (2R, 4R)-1-(NG-니트로-L-아르기닐)-4-메틸-2-피페리딘카르복시산 흰색 고체를 수득하였다.27.3 g of an arginine derivative ethyl (2R, 4R) -1- [N G -nitro-N 2- (tert-butoxycarbonyl) -L-arginyl) -4-methyl-2-piperidinecarboxylic acid is solvent It was dissolved in 130 mL of phosphorus methylene chloride. This was added dropwise at room temperature to a solution of 21.6 g of B-chlorocatecholborane, halocatecholborane, dissolved in 500 mL of methylene chloride as a solvent. After stirring for 1 hour at room temperature, 130 mL of water was added and stirred for 20 minutes, and diluted with 1,000 mL of methylene chloride. This solution was washed twice with 200 mL of 10% aqueous sodium hydroxide solution and once with 200 mL of saturated sodium chloride solution. The organic layer separated as above was dried over anhydrous magnesium sulfate, and the solvent was distilled under reduced pressure to give 25.1 g of ethyl (2R, 4R) -1- (N G -nitro-L-arginyl) -4-methyl-2-pi. Ferridinecarboxylic acid white solid was obtained.
(아릴기가 결합된 아르기닌 유도체 제조)(Manufacture of arginine derivative in which aryl group is bonded)
상기 수득한 에틸 (2R, 4R)-1-(NG-니트로-L-아르기닐)-4-메틸-2-피페리딘카르복시산 24.7 g을 용매인 클로로포름 200 mL에 녹인 후, 5 ℃를 유지하였다. 여기에 삼차아민인 피리딘 5.8 g과 아릴설포닐할라이드 화합물인 3-메틸-퀴놀린설포닐클로라이드 14.8 g을 순서대로 투입하였다. 이를 상온에서 3 시간 동안 교반한후, 반응용액을 물 50 mL로 2회 세척하였다. 상기와 같이 분리된 유기층을 무수 황산마그네슘으로 건조하고 용매를 감압증류하여 관크로마토그래피법(클로로포름 : 메틸알코올 = 20 : 1)으로 정제하여 33.1 g의 비결정형 고체인 에틸 (2R, 4R)-1-[NG-니트로-N2-(3-메틸-8-퀴놀린설포닐)-L-아르기닐)-4-메틸-2-피페리딘카르복시산 28.4 g을 수득하였다.24.7 g of the ethyl (2R, 4R) -1- (N G -nitro-L-arginyl) -4-methyl-2-piperidinecarboxylic acid obtained above was dissolved in 200 mL of chloroform as a solvent, and then maintained at 5 ° C. It was. To this, 5.8 g of pyridine as a tertiary amine and 14.8 g of 3-methyl-quinolinesulfonyl chloride as an arylsulfonyl halide compound were added in this order. After stirring for 3 hours at room temperature, the reaction solution was washed twice with 50 mL of water. The organic layer separated as described above was dried over anhydrous magnesium sulfate, the solvent was distilled under reduced pressure, and the residue was purified by column chromatography (chloroform: methyl alcohol = 20: 1) to obtain 33.1 g of an amorphous solid, ethyl (2R, 4R) -1. 28.4 g of-[N G -nitro-N 2- (3-methyl-8-quinolinesulfonyl) -L-arginyl) -4-methyl-2-piperidinecarboxylic acid were obtained.
비교예Comparative example
(tert-부톡시카보닐기 제거된 아르기닌 유도체 제조)(Preparation of tert-butoxycarbonyl group removed arginine derivative)
아르기닌 유도체인 에틸 (2R, 4R)-1-[NG-니트로-N2-(tert-부톡시카보닐)-L-아르기닐)-4-메틸-2-피페리딘카르복시산 30 g을 용매인 초산에틸 30 mL에 녹인 후, 0 ℃를 유지하면서 10% 무수 염화수소 초산에틸 용액 80 mL를 가하였다. 이를 3 시간 동안 교반한 후, 에틸에테르 200 mL를 가하였다. 이때 흰색 고체가 얻어지나, 곧 수분을 흡수하여 젤 형태의 생성물이 얻어지는데, 이 생성물을 에틸에테르로 세척하여 에틸 (2R, 4R)-1-(NG-니트로-L-아르기닐)-4-메틸-2-피페리딘카르복시산 염산염을 수득하였다.30 g of arginine derivative ethyl (2R, 4R) -1- [N G -nitro-N 2- (tert-butoxycarbonyl) -L-arginyl) -4-methyl-2-piperidinecarboxylic acid After dissolving in 30 mL of ethyl acetate phosphorus, 80 mL of 10% anhydrous ethyl chloride acetate solution was added while maintaining 0 ° C. After stirring for 3 hours, 200 mL of ethyl ether was added. At this point, a white solid was obtained, but soon absorbed moisture to give a gel-like product, which was washed with ethyl ether to give ethyl (2R, 4R) -1- (N G -nitro-L-arginyl) -4 -Methyl-2-piperidinecarboxylic acid hydrochloride was obtained.
(아릴기가 결합된 아르기닌 유도체 제조)(Manufacture of arginine derivative in which aryl group is bonded)
에틸 (2R, 4R)-1-(NG-니트로-L-아르기닐)-4-메틸-2-피페리딘카르복시산 염산염 25 g을 용매인 클로로포름 200 mL에 녹인 후, 5 ℃를 유지하였다. 여기에 삼차아민인 트리에틸아민 13.6 g과 아릴설포닐할라이드 화합물인 3-메틸-퀴놀린설포닐클로라이드 14.7 g을 순서대로 투입하였다. 이를 상온에서 3 시간 동안 교반한 후, 반응용액을 물 50 mL로 2회 세척하였다. 상기와 같이 분리된 유기층을 무수 황산마그네슘으로 건조하고 용매를 감압증류하여 관크로마토그래피법(클로로포름 : 메틸알코올 = 20 : 1)으로 정제하여 32.5 g의 비결정형 고체인 에틸 (2R, 4R)-1-[NG-니트로-N2-(3-메틸-8-퀴놀린설포닐)-L-아르기닐)-4-메틸-2-피페리딘카르복시산 22.1 g을 수득하였다.25 g of ethyl (2R, 4R) -1- (N G -nitro-L-arginyl) -4-methyl-2-piperidinecarboxylic acid hydrochloride was dissolved in 200 mL of chloroform as a solvent, and then maintained at 5 ° C. 13.6 g of triethylamine as a tertiary amine and 14.7 g of 3-methyl-quinolinesulfonyl chloride as an arylsulfonyl halide compound were added thereto in this order. After stirring for 3 hours at room temperature, the reaction solution was washed twice with 50 mL of water. The organic layer separated as described above was dried over anhydrous magnesium sulfate, the solvent was distilled under reduced pressure, and the residue was purified by column chromatography (chloroform: methyl alcohol = 20: 1) to give 32.5 g of an amorphous solid, ethyl (2R, 4R) -1. 22.1 g of-[N G -nitro-N 2- (3-methyl-8-quinolinesulfonyl) -L-arginyl) -4-methyl-2-piperidinecarboxylic acid were obtained.
실험예Experimental Example
상기 실시예 1 또는 2, 및 비교예에서 제조한 tert-부톡시카보닐기가 제거된 아르기닌 유도체의 흡습에 의한 조해성, 및 수율을 측정하고, 최종생성물인 아릴기가 결합된 아르기닌 유도체의 수율을 측정하여, 그 결과를 하기 표 1에 나타내었다.Determination and dehydration of the arginine derivative obtained by removing the tert-butoxycarbonyl group prepared in Example 1 or 2, and Comparative Example, and the yield, and measuring the yield of the arginine derivative bonded to the aryl group as the final product The results are shown in Table 1 below.
상기 표 1을 통하여, 본 발명의 제조방법에 따라 할로카테콜보란을 사용한 실시예 1, 및 실시예 2의 보호기가 제거된 아르기닌 유도체는 흡습에 의한 조해성이 해결되었으나, 무수 조건의 염산(HCl)을 사용한 비교예는 조해성이 해결되지 않았다. 또한 본 발명의 실시예 1, 및 실시예 2는 삼차아민의 사용량을 비교예의1/2 배로 감소시킬 수 있었으며, 수율 또한 비교예보다 월등함을 확인할 수 있었다.Through Table 1, the arginine derivatives of the protecting groups of Example 1 and Example 2 using halocatecholborane according to the preparation method of the present invention have been solved by hygroscopic, hydrochloric acid (HCl) in anhydrous conditions The comparative example using did not solve the deliquescent property. In addition, Example 1, Example 2 of the present invention was able to reduce the amount of the tertiary amine to 1/2 times the comparative example, it was confirmed that the yield is also superior to the comparative example.
상기에서 살펴본 바와 같이, 본 발명의 제조방법에 따르면 보호기인 tert-부틸옥시카보닐기(카바메이트) 제거 단계에서 생성되는 염산염 형태의 반응중간체의 흡습에 의한 조해성을 해결하고, 동시에 삼차아민 염기의 사용량을 감소시킬 수 있을 뿐만 아니라, 반응 조건이 용이하고 고수율로 아르기닌 유도체의 제조할 수 있는 효과가 있다.As described above, according to the production method of the present invention to solve the deliquescent property by the absorption of the reaction intermediate in the form of hydrochloride in the tert-butyloxycarbonyl group (carbamate) removal step of protecting group, and at the same time the amount of tertiary amine base In addition to reducing the reaction conditions, the reaction conditions are easy and there is an effect that can be produced in the arginine derivative in a high yield.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020020002053A KR20030061524A (en) | 2002-01-14 | 2002-01-14 | Method for preparing arginine derivatives |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020020002053A KR20030061524A (en) | 2002-01-14 | 2002-01-14 | Method for preparing arginine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20030061524A true KR20030061524A (en) | 2003-07-22 |
Family
ID=32217963
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020020002053A KR20030061524A (en) | 2002-01-14 | 2002-01-14 | Method for preparing arginine derivatives |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20030061524A (en) |
-
2002
- 2002-01-14 KR KR1020020002053A patent/KR20030061524A/en not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5852573B2 (en) | Method for producing 1-triazole-2-butanol derivative | |
JP4770174B2 (en) | Process for producing glutamic acid derivative and pyroglutamic acid derivative, and novel production intermediate | |
US10988438B2 (en) | Process for the preparation of a nitric oxide donating prostaglandin analogue | |
EA015801B1 (en) | Optically active carbamates, process for preparation thereof and use thereof as pharmaceutical intermediates | |
CZ20014548A3 (en) | Preparation of substituted piperidin-4-ones | |
US6197998B1 (en) | Process for producing N-glycyltyrosine and its crystal structure | |
KR20030061524A (en) | Method for preparing arginine derivatives | |
CN114845991B (en) | Method for synthesizing melphalan | |
JPH02256655A (en) | Production of optically active threo-dihydroxyphenylserine derivative | |
KR20040042637A (en) | Method for preparing arginine derivatives | |
EP2473492B1 (en) | Process for the preparation of (1s,4r)-2-oxa-3-azabicyclo[2,2.1]hept-5-enes | |
JP4529116B2 (en) | Method for producing high-purity tritylpiperazine derivative | |
CN113549070B (en) | Preparation method of malavisuo and derivatives thereof | |
JP4749579B2 (en) | (Meth) acryloyl group-containing carbamic acid halides and method for producing the same | |
US6355804B1 (en) | Process for producing piperidinecarboxylic acid amide derivatives | |
KR20030047466A (en) | Optical resolution of racemic piperidine carboxylic acid derivative | |
JP3008227B2 (en) | Menthyl N- (2-fluorocyclopropyl) carbamate derivative and method for producing the same | |
US6706888B2 (en) | Processes for preparing imidazole derivatives and salts thereof | |
US20040220417A1 (en) | Processes for preparation of n-protected-beta-amino alcohols and n-protected-beta-amino epoxides | |
KR0150566B1 (en) | A process for preparing stereo active 3-amino heterocyclic compound | |
WO2020148777A1 (en) | Process for preparation of glycopyrrolate intermediate | |
JPH0233036B2 (en) | ||
JP2008285439A (en) | Method for producing alacepril | |
PL200215B1 (en) | Method for manufacture of diastereoisomerically and enantiomerically pure amines | |
JPH08509970A (en) | Process for producing NG-monoalkyl-L-arginine and related compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Withdrawal due to no request for examination |